| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer JM Mehnert, A Varga, MS Brose, RR Aggarwal, CC Lin, A Prawira, ... BMC cancer 19, 1-9, 2019 | 195 | 2019 |
| Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies P Schöffski, DSW Tan, M Martín, M Ochoa-de-Olza, J Sarantopoulos, ... Journal for immunotherapy of cancer 10 (2), 2022 | 128 | 2022 |
| Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review A Prawira, SF Oosting, TW Chen, R Saluja, L Wang, LL Siu, KKW Chan, ... British journal of cancer 117 (12), 1743-1752, 2017 | 89 | 2017 |
| Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial C Aggarwal, A Prawira, S Antonia, O Rahma, A Tolcher, RB Cohen, Y Lou, ... Journal for immunotherapy of cancer 10 (4), 2022 | 87 | 2022 |
| Phase I/II study of LAG525±spartalizumab (PDR001) in patients (pts) with advanced malignancies. DS Hong, P Schoffski, A Calvo, J Sarantopoulos, M Ochoa De Olza, ... Journal of Clinical Oncology 36 (15_suppl), 3012-3012, 2018 | 75 | 2018 |
| Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. JM Mehnert, A Varga, M Brose, RR Aggarwal, CC Lin, A Prawira, ... Journal of Clinical Oncology 34 (15_suppl), 6091-6091, 2016 | 59 | 2016 |
| Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): phase II trial of high dose pantoprazole (autophagy inhibitor) with docetaxel in metastatic … AR Hansen, IF Tannock, A Templeton, E Chen, A Evans, J Knox, ... The Oncologist 24 (9), 1188-1194, 2019 | 43 | 2019 |
| Rural oncology: overcoming the tyranny of distance for improved cancer care M George, P Ngo, A Prawira Journal of Oncology Practice 10 (3), e146-e149, 2014 | 42 | 2014 |
| Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study M Oliva, D Chepeha, DV Araujo, JJ Diaz-Mejia, P Olson, A Prawira, ... Journal for Immunotherapy of Cancer 9 (10), 2021 | 41 | 2021 |
| Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck D Day, A Prawira, A Spreafico, J Waldron, R Karithanam, M Giuliani, ... Oral Oncology 108, 104753, 2020 | 31 | 2020 |
| Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors JC Bendell, P Bedard, YJ Bang, P LoRusso, S Hodi, M Gordon, ... Cancer Research 80 (16), 2020 | 23 | 2020 |
| Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid … JC Bendell, P Bedard, YJ Bang, P LoRusso, S Hodi, M Gordon, ... Cancer Research 80 (16_Supplement), CT302-CT302, 2020 | 21 | 2020 |
| Data resources for the identification and interpretation of actionable mutations by clinicians A Prawira, TJ Pugh, TL Stockley, LL Siu Annals of Oncology 28 (5), 946-957, 2017 | 21 | 2017 |
| Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein. JR Infante, PL Bedard, G Shapiro, TM Bauer, A Prawira, O Laskin, ... Journal of Clinical Oncology 35 (15_suppl), 2574-2574, 2017 | 19 | 2017 |
| A rare case of paclitaxel and/or trastuzumab induced acute hepatic necrosis H Mandaliya, P Baghi, A Prawira, MK George Case reports in oncological medicine 2015 (1), 825603, 2015 | 18 | 2015 |
| Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group HH Loong, T Shimizu, A Prawira, AC Tan, B Tran, D Day, DSP Tan, ... ESMO open 8 (4), 101586, 2023 | 14 | 2023 |
| A phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors B Markman, B Tran, H Gan, A Prawira, J Coward, X Jin, B Li, M Wang, ... J Immunother Cancer 7 (Suppl 1), 283, 2019 | 12 | 2019 |
| 1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies M Millward, S Frentzas, HK Gan, A Prawira, B Tran, J Coward, X Jin, B Li, ... Annals of Oncology 31, S705-S706, 2020 | 11 | 2020 |
| Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced … A Prawira, I Brana-Garcia, A Spreafico, A Hope, J Waldron, ARA Razak, ... Investigational new drugs 34, 575-583, 2016 | 11 | 2016 |
| SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study. M Oliva Bernal, DV Araujo, DB Chepeha, A Prawira, A Spreafico, ... Journal of Clinical Oncology 38 (15_suppl), 6569-6569, 2020 | 10 | 2020 |
